Caribou Biosciences Inc
Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and autoimmune diseases in the United States and internationally. The company's lead product candidate include CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapse… Read more
Market Cap & Net Worth: Caribou Biosciences Inc (CRBU)
Caribou Biosciences Inc (NASDAQ:CRBU) has a market capitalization of $184.13 Million ($184.13 Million) as of March 19, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #15516 globally and #6090 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Caribou Biosciences Inc's stock price $1.97 by its total outstanding shares 93468038 (93.47 Million).
Caribou Biosciences Inc Market Cap History: 2021 to 2026
Caribou Biosciences Inc's market capitalization history from 2021 to 2026. Data shows change from $1.41 Billion to $184.13 Million (-36.52% CAGR).
Index Memberships
Caribou Biosciences Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.24 Trillion | 0.01% | #417 of 976 |
|
NASDAQ Composite
IXIC
|
$33.39 Trillion | 0.00% | #1472 of 3165 |
Weight: Caribou Biosciences Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Caribou Biosciences Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Caribou Biosciences Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
13.32x
Caribou Biosciences Inc's market cap is 13.32 times its annual revenue
1728.56x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $1.41 Billion | $9.60 Million | -$66.92 Million | 146.95x | N/A |
| 2022 | $586.98 Million | $13.85 Million | -$99.42 Million | 42.38x | N/A |
| 2023 | $535.57 Million | $34.48 Million | -$102.07 Million | 15.53x | N/A |
| 2024 | $148.61 Million | $9.99 Million | -$149.10 Million | 14.87x | N/A |
| 2025 | $148.61 Million | $11.16 Million | -$148.12 Million | 13.32x | N/A |
Competitor Companies of CRBU by Market Capitalization
Companies near Caribou Biosciences Inc in the global market cap rankings as of March 19, 2026.
Key companies related to Caribou Biosciences Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Caribou Biosciences Inc Historical Marketcap From 2021 to 2026
Between 2021 and today, Caribou Biosciences Inc's market cap moved from $1.41 Billion to $ 184.13 Million, with a yearly change of -36.52%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $184.13 Million | +23.90% |
| 2025 | $148.61 Million | 0.00% |
| 2024 | $148.61 Million | -72.25% |
| 2023 | $535.57 Million | -8.76% |
| 2022 | $586.98 Million | -58.38% |
| 2021 | $1.41 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Caribou Biosciences Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $184.13 Million USD |
| MoneyControl | $184.13 Million USD |
| MarketWatch | $184.13 Million USD |
| marketcap.company | $184.13 Million USD |
| Reuters | $184.13 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.